Document Detail

Thymoma-a clinico-pathological long-term study with emphasis on histology and adjuvant radiotherapy dose.
MedLine Citation:
PMID:  23154559     Owner:  NLM     Status:  In-Data-Review    
INTRODUCTION: : To evaluate prognostic factors of thymic epithelial tumors (TETs) with particular reference to histology and the dose-response relationship of adjuvant radiotherapy.
METHODS: : Retrospective study with central pathological review on patients resected for TET between 1966 and 2004 at a single institution. Prognostic factors were identified using Cox regression analysis.
RESULTS: : From 93 patients with TET, 33.3% relapsed and 47.3% died. Cause of death was known in 64% and attributed to TET in 25%. Myasthenia gravis was associated with superior disease-free survival (DFS) and overall survival (OS). Tumors smaller than 8.5 cm had a significantly better prognosis. With a median follow-up of 9.8 years actuarial OS at 5, 10, and 20 years were 96%, 92%, and 47% in stage I; 85%, 61%, and 53% in stage II; 72%, 39%, and 15% in stage III and IV. Advanced stage and incomplete resection had a negative impact on DFS and OS. According to histology (WHO type A, AB, B1; favorable; versus WHO type B2, B3; intermediate; versus thymic carcinoma, unfavorable) three prognostic groups were discernible. On multivariate analysis, tumor size, and stage emerged as prognostic factors, but neither histology nor myasthenia. Postoperative radiotherapy was administered in 27 patients (median dose 50.8 Gy). Doses in excess of 50 Gy were associated with significantly improved DFS and OS.
CONCLUSIONS: : Tumor stage, histology, complete resection, and tumor size had a significant impact on survival. Myasthenia may facilitate early detection and is correlated with superior survival. When postoperative radiotherapy is administered, doses above 50 Gy may improve outcome.
Thomas Harnath; Alexander Marx; Philipp Ströbel; Edwin Bölke; Reinhart Willers; Stephan Gripp
Related Documents :
24055249 - Determination of a predictive cutoff value of nt-probnp testing for long-term survival ...
23547079 - 90yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage folli...
24692119 - Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogen...
24473399 - Phase ii study of trastuzumab in combination with s-1 plus cisplatin in her2-positive g...
24045669 - Randomised phase ii study of s-1/cisplatin plus tsu-68 vs s-1/cisplatin in patients wit...
23042019 - Non-tbi hematopoietic stem cell transplantation in pediatric aml patients: a single-cen...
18706269 - Treatment of diffuse large b-cell lymphoma in the elderly: strategies integrating oncog...
12525529 - Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelio...
9358089 - Conservative surgery in high-risk epithelial ovarian carcinoma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer     Volume:  7     ISSN:  1556-1380     ISO Abbreviation:  J Thorac Oncol     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101274235     Medline TA:  J Thorac Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1867-71     Citation Subset:  IM    
*Department of Radiation Oncology, University Hospital at Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; †Department of Pathology, Medical Faculty Mannheim University of Heidelberg, Mannheim, Germany; and ‡Department of Biostatisitcs, University Hospital Düsseldorf, Duesseldorf, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the ...
Next Document:  Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.